March 13, 2018 - By Ivan Hodges

The stock of TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) registered a decrease of 7.13% in short interest. TLOG’s total short interest was 66,400 shares in March as published by FINRA. Its down 7.13% from 71,500 shares, reported previously. With 107,600 shares average volume, it will take short sellers 1 days to cover their TLOG’s short positions. The short interest to TETRALOGIC PHARMACEUTICALS CORP’s float is 0.45%.

It closed at $0.0272 lastly. It is down 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. The company has market cap of $665,450. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. It currently has negative earnings. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.

More notable recent TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) news were published by: Globenewswire.com which released: “TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata” on November 02, 2015, also Globenewswire.com with their article: “TetraLogic Provides Update on Hepatitis B Clinical Program” published on July 20, 2015, Businesswire.com published: “Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to …” on November 02, 2016. More interesting news about TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) were released by: Globenewswire.com and their article: “TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC …” published on December 29, 2016 as well as Seekingalpha.com‘s news article titled: “TetraLogic Pharma -69% after birinapant study shows no clinical benefit” with publication date: January 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.